New insights into how dacarbazine may alter melanoma response to therapy
Recent findings reported by the RNF press service suggest that the cancer drug dacarbazine could influence how melanoma cells react to treatment, potentially increasing resistance in some cases. Melanoma ranks as the most dangerous form of skin cancer, not only because it arises with little warning in many patients, but also due to its ability to spread. Detecting it early is often challenging, and metastasis is a common turning point that complicates management. In addition, melanoma exhibits a variety of phenotypes, which helps the disease adapt to therapies and partly explains why resistance to drugs can develop. In some instances, melanoma cells can even enter a dormant state where division slows or halts temporarily, making them harder to target with conventional treatments.
Researchers from Krasnoyarsk State Medical University, along with collaborating teams from other institutions, undertook studies to understand how dacarbazine interacts with melanoma at the cellular level. The drug is designed to interfere with the DNA of cancer cells, aiming to stop replication. However, the study indicates that this interference may carry unintended consequences for tumor biology and treatment outcomes. These observations emerge from experiments where melanoma cultures were exposed to dacarbazine, followed by comprehensive examination of gene activity. The results showed a striking decline in the number of actively dividing cells, roughly by a factor of nine. This change was linked to the upregulation of genes associated with a resting or quiescent state. While this shift hints at a form of stress response, it did not conclusively prove that the cells had aged, and it raised the possibility that some cells might later resume activity.
The investigation also showed that multiple gene pathways connected to cell cycle control, DNA integrity, and the signaling processes that influence the growth of blood vessels were affected by dacarbazine exposure. The disruption of these pathways can lead to unpredictable cellular behavior, increasing the likelihood of errors in cell division or enabling cancer cells to survive under treatment pressure. The researchers note that insufficient blood vessel formation can limit tumor growth and spread, while the drug’s active component may not reach certain tumor regions as effectively when the vascular network is altered. As a result, a subpopulation of cells with a tendency to adhere to surfaces and resist therapy—the so-called static or surface-adapted pool—may emerge. This pool engages with the body in atypical ways, offering a potential shield against standard treatments. [Citation: Krasnoyarsk State Medical University study; RNF report]
The team emphasizes that these findings do not close the door on dacarbazine as a therapy but rather highlight a potential mechanism by which resistance could arise. They stress the importance of understanding the conditions that foster dormancy and surface-adapted states in melanoma cells, as these states may influence how tumors respond to chemotherapy in the clinic. In the near term, researchers plan to investigate whether the dormant-like or surface-adapted cells possess specific vulnerabilities that could be exploited to improve treatment efficacy and prevent relapse. The ultimate goal is to translate these laboratory observations into strategies that better predict patient responses and guide combination therapies that counteract resistance. [Citation: Krasnoyarsk State Medical University study; RNF report]
Alongside these scientific updates, a broader view on melanoma emphasizes that ongoing research continues to refine the understanding of how tumors evolve under drug pressure. By examining gene activity and cellular states, scientists aim to map how cancer cells adapt and when they might become susceptible to targeted interventions. Such knowledge could inform clinical decisions, helping clinicians select therapeutic regimens that minimize resistance while maximizing tumor control. [Citation: Krasnoyarsk State Medical University study; RNF report]
Future work will concentrate on validating potential weaknesses within dormant-like melanoma cells and identifying treatment combinations that can prevent the emergence of resistant populations. The pursuit of these discoveries reflects a continuous effort to improve outcomes for patients facing melanoma, with the hope that new approaches will render resistant cells more vulnerable and reduce relapse rates. [Citation: Krasnoyarsk State Medical University study; RNF report]
Ancient Russian biologists discoveredLife in captivity has changed the shape of the tiger’s skull.